ABUS
Arbutus Biopharma CorpCompany Information
- Company Name
- Arbutus Biopharma Corp
- CIK
- CIK0001447028
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ABUS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ABUS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-02-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 85,500
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 141,480,945
- Shares outstanding
- 197,470,724
- Ownership
- 71.65%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 12.20%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 24 | 18 | 22 | 37 | 37 | 36 | 32 | 63 | 43 | 26 | 18 | ||||||
| Short Term Investments | - | - | 73 | - | - | - | 86 | - | - | - | 100 | - | ||||||
| Available For Sale Securities Debt Securities Current | 73 | 72 | - | 71 | 61 | 76 | - | 96 | 79 | 86 | - | 117 | ||||||
| Accounts Receivable Net Current | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Accounts And Other Receivables Net Current | 179 | 179 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 2 | 3 | 4 | 3 | 2 | 3 | 4 | 4 | 4 | 5 | ||||||
| Assets Current | 274 | 277 | 94 | 97 | 103 | 117 | 127 | 133 | 148 | 136 | 132 | 142 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 4 | 4 | 5 | 5 | ||||||
| Long Term Investments | - | - | 0 | - | - | - | 0 | 3 | 7 | 9 | 6 | 10 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Assets | 274 | 277 | 95 | 98 | 103 | 117 | 132 | 140 | 160 | 150 | 144 | 159 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 4 | 5 | 5 | 5 | 12 | 8 | 8 | 11 | 8 | 10 | 10 | ||||||
| Deferred Revenue Current | - | - | 0 | 0 | 0 | 7 | 8 | 11 | 11 | 12 | 12 | 12 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Liabilities Current | 3 | 5 | 6 | 5 | 5 | 19 | 16 | 19 | 23 | 20 | 22 | 22 | ||||||
| Deferred Revenue Noncurrent | - | - | 0 | 0 | 0 | 3 | 3 | - | - | - | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 9 | 9 | 8 | 11 | 11 | 11 | 10 | 8 | 8 | 8 | 8 | 7 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 15 | 17 | 18 | 20 | 20 | 38 | 34 | 34 | 38 | 36 | 38 | 39 | ||||||
Statement Of Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1,448 | 1,444 | 1,421 | 1,419 | 1,417 | 1,416 | 1,410 | 1,408 | 1,403 | 1,377 | 1,350 | 1,346 | ||||||
| Additional Paid In Capital | 74 | 74 | 83 | 83 | 83 | 82 | 82 | 81 | 82 | 80 | 81 | 80 | ||||||
| Retained Earnings Accumulated Deficit | -1,216 | -1,210 | -1,380 | -1,376 | -1,369 | -1,371 | -1,347 | -1,334 | -1,314 | -1,295 | -1,277 | -1,257 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -48 | -48 | -48 | -48 | -48 | -48 | -48 | -48 | -48 | -48 | -48 | -49 | ||||||
| Stockholders Equity | 259 | 260 | 77 | 77 | 83 | 79 | 97 | 107 | 122 | 115 | 106 | 119 | ||||||
| Liabilities And Stockholders Equity | 274 | 277 | 95 | 98 | 103 | 117 | 132 | 140 | 160 | 150 | 144 | 159 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 0 | 0 | - | 13 | 13 | 13 | - | 13 | 13 | 12 | - | 12 | ||||||
| Common Stock Shares Issued | 198 | 197 | 193 | 192 | 192 | 191 | 190 | 189 | 189 | 180 | 170 | 168 | ||||||
| Shares Outstanding | 198 | 197 | 193 | 192 | 192 | 191 | 190 | 189 | 189 | 180 | 170 | 168 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArbutus Biopharma Corp (ABUS) — SEC Financial Statements & Analysis
Arbutus Biopharma Corp (ABUS) is a pharmaceutical preparations company, incorporated in A1. Arbutus Biopharma Corp trades on Nasdaq as: ABUS. Arbutus Biopharma Corp (ABUS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Arbutus Biopharma Corp carries a market cap of $947.86M, a P/E ratio of 6.19x, a P/B ratio of 3.66x, a P/S ratio of 5.22x, an enterprise value of $928.69M, and an EV/EBITDA multiple of 6.23x. On profitability, it posts a gross margin of 101.67%, an operating margin of 81.99%, a net margin of 84.23%, a Return on Equity (ROE) of 89.58%, a Return on Assets (ROA) of 81.13%, and a Return on Invested Capital (ROIC) of 103.09%. Per share, it reports EPS of $0.78, diluted EPS of $0.78, free cash flow per share of $-0.12, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1078.78% year-over-year, net income growth of -382.12% year-over-year, and EPS growth of -373.66% year-over-year. On the balance sheet, it maintains a current ratio of 81.42x, a quick ratio of 80.97x, working capital of $270.52M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of 1960.46x, free cash flow of $-24.63M (TTM), and net debt of $-19.17M. Figures sourced from SEC EDGAR.
- Market Cap
- $947.86M
- P/E TTM
- 6.19x
- EPS TTM
- $0.78
- P/B TTM
- 3.66x
- ROE TTM
- 89.58%
- ROA TTM
- 81.13%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-24.63M
- Net Revenue TTM Growth 1Y
- 1078.78%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Arbutus Biopharma Corp in?
Arbutus Biopharma Corp (ABUS) operates in the Pharmaceutical Preparations industry.
What exchange does ABUS trade on?
Arbutus Biopharma Corp (ABUS) trades on the Nasdaq.
Where is Arbutus Biopharma Corp incorporated?
Arbutus Biopharma Corp is incorporated in British Columbia, Canada.
When was Arbutus Biopharma Corp (ABUS)'s most recent SEC filing?
Arbutus Biopharma Corp (ABUS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ABUS's market cap?
Arbutus Biopharma Corp (ABUS) has a market capitalization of $947.86M as of 2026-06-30.
What is ABUS's P/E ratio?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month P/E ratio is 6.19x as of 2026-06-30.
What is ABUS's EPS (earnings per share)?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month EPS is $0.78 as of 2026-06-30.
What is ABUS's ROE (return on equity)?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month Return on Equity (ROE) is 89.58% as of 2026-06-30.
What is ABUS's ROA (return on assets)?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month Return on Assets (ROA) is 81.13% as of 2026-06-30.
What is ABUS's ROIC (return on invested capital)?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month Return on Invested Capital (ROIC) is 103.09% as of 2026-06-30.
What is ABUS's EV/EBITDA?
Arbutus Biopharma Corp (ABUS)'s trailing twelve month EV/EBITDA is 6.23x as of 2026-06-30.